Market Research Logo

Global Ophthalmic Drugs Market Forecast 2018-2028

Global Ophthalmic Drugs Market Forecast 2018-2028

The global ophthalmic drugs market is expected to grow at a CAGR of 4.4% in the first half of the forecast period. The market is expected to grow at a CAGR of 4.8% from 2017-2028. The market is estimated at $24bn in 2017, dominated by the retinal disorder drugs segment.

How this report will benefit you

Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 298-page report you will receive 123 tables and 113 figures– all unavailable elsewhere.

The 298-page report provides clear detailed insight into the global ophthalmic drugs market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand-new report today you stay better informed and ready to act.

Report Scope

  • Global Ophthalmic Drugs market forecasts from 2017-2028
  • This report also breaks down the revenue forecasts to 2028 for the global ophthalmic drugs market by the leading submarkets:
  • Retinal Disorder Drugs
  • Allergic, Inflammatory & Infective Drugs
  • Glaucoma Drugs
  • Dry Eye Drugs
  • Other Ophthalmic Drugs
  • This report includes revenue forecasts to 2028 for the following ophthalmic drugs:
  • Eylea
  • Lucentis
  • Avastin
  • Visudyne
  • Jetrea
  • Pataday
  • Vigamox
  • Patanol
  • TobraDex
  • Cravit
  • AzaSite
  • Acular
  • Lumigan and Ganfort
  • Xalatan/Xalacom
  • Travatan/Travatan Z and DuoTrav
  • Alphagan/Alphagan P and Combigan
  • Azopt
  • Trusopt
  • Zioptan
  • Cosopt
  • Tapros/Taflotan
  • Restasis
  • Refresh
  • Hyalein
  • Diquas
  • This report provides individual revenue forecasts to 2028 for these national markets:
  • The US
  • Japan
  • EU5: Germany, France, the UK, Spain, Italy
  • Russia
  • China
  • India
  • Brazil
  • Rest of the World
  • Our study provides a SWOT analysis and discusses Porter’s Five Forces analysis that influence the global ophthalmic drugs market
  • Our report provides discussion on the ophthalmic drugs that are currently in the development pipeline
  • Our study discusses the selected leading companies that are the major players in the ophthalmic drugs industry:
  • Novartis
  • Regeneron
  • Allergan
  • Roche
  • Valeant
  • Santen
  • Bayer
  • Pfizer
  • Senju
Visiongain’s study is intended for anyone requiring commercial analyses for the global ophthalmic drugs market. You find data, trends and predictions.

Please Note: Prior to initiating fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.

The publisher is using a password system to access all reports. Single user (non-printable) and departmental licenses expires after 12 month period. In the case of departmental site license purchases, the publisher requires all email addresses for the licensed users prior to fulfillment.


1. Report Overview
1.1 Global Ophthalmic Drugs: Market Overview
1.2 Global Ophthalmic Drugs Market Segmentation
1.3 Why You Should Read This Report
1.4 How This Report Delivers
1.5 Key Questions Answered by This Analytical Report
1.6 Who Is This Report For?
1.7 Methodology
1.8 Frequently Asked Questions (FAQ)
1.9 Associated Reports
1.10 About Visiongain
2. An Introduction to Ophthalmic Drugs
2.1 The Pharmaceutical Industry: A Brief Introduction
2.1.1 Ophthalmic Treatments – An Industry Overview
2.2 The Human Eyes – Structurally Delicate and Functionally Intricate Organs
2.3 The Global Burden of Eye Disease
2.4 Ophthalmic Drugs: Market Segmentation
2.5 Glaucoma: A Major Cause of Vision Loss
2.5.1 A Classification of Glaucoma
2.5.1.1 Primary Open-Angle Glaucoma
2.5.1.2 Acute Angle-Closure Glaucoma
2.5.1.3 Congenital Glaucoma
2.5.1.4 Secondary Glaucoma
2.5.1.5 Normal-Tension Glaucoma
2.5.1.6 Ocular Hypertension
2.5.2 Risk Factors for Glaucoma
2.5.3 Diagnosis of Glaucoma
2.5.4 Drug Treatment of Glaucoma
2.5.5 Laser Treatment and Surgery for Glaucoma
2.6 Age-Related Macular Degeneration (AMD)
2.6.1 Dry (non-exudative) AMD
2.6.2 Wet (exudative) AMD
2.6.3 Risk Factors for AMD
2.6.4 Diagnosis of AMD
2.6.5 Treatment of AMD
2.7 Diabetic Retinopathy (DR)
2.7.1 Diagnosis of Diabetic Retinopathy
2.7.2 Risk factor of Diabetic Retinopathy
2.7.3 Treatment of Diabetic Retinopathy
2.8 Ocular Allergy and Allergic Conjunctivitis
2.8.1 Diagnosis of Ocular Allergy
2.8.2 Treatment of Ocular Allergy
2.9 Ocular Inflammatory Disease
2.9.1 Risk factors of Ocular Inflammatory Disease
2.9.2 Treatment of Ocular Inflammatory Disease
2.10 Eye Infections
2.10.1 Treatment of Eye Infections
2.11 Dry Eye Syndrome
2.11.1 Treatment of Dry Eye Syndrome
2.12 Phases of Clinical Trials
2.13 Ophthalmic Drugs: Market Definition in This Report
3. The Global Ophthalmic Drugs Market, 2017-2028
3.1 The Global Ophthalmic Drugs Market: Market Overview
3.2 Categorisation of the Global Ophthalmic Drugs Market
3.3 The Global Ophthalmic Drugs Market In 2017
3.4 The Global Ophthalmic Drugs Market: Market Forecast 2017-2028
3.5 Ophthalmic Drugs: Changing Market Shares by Sector 2017-2028
4. The Retinal Disorder Drugs Market: Market Analysis and Forecast 2017-2028
4.1 Leading Products in the Retinal Disorder Drugs Market, 2017
4.2 Retinal Disorders: Market Trends and Developments, 2016
4.2.1 The Rise of Eylea
4.2.2 The Debate Around Off-Label Avastin Use and The Role of Novartis And Roche
4.2.3 How Likely Is Avastin’s Expansion into Age-Related Macular Degeneration?
4.2.4 Jetrea: Underwhelming Sales Cause ThromboGenics to Switch Focus to Their Pipeline
4.2.5 Drug/Device Combination Products Entering the Market
4.2.6 Does Regenerative Medicine Have a Successful Future in Ophthalmics?
4.3 Retinal Disorder Drugs: Market Forecast 2017-2028
4.3.1 Retinal Disorder Drugs: Changing Market Shares by Leading Drugs 2017-2028
4.4 Leading Drugs for The Treatment of Retinal Disorders
4.5 Eylea (aflibercept) - Regeneron/ Bayer/ Santen
4.5.1 Recent Approvals for Eylea
4.5.2 Eylea: Superior Clinical Outcomes than Lucentis and Avastin?
4.5.3 Eylea: Sales Forecast 2017-2028
4.5.4 Possible Combination Therapies Involving Eylea
4.6 Lucentis (ranibizumab) – Roche/ Novartis
4.6.1 Lucentis: Sales Forecast 2017-2028
4.6.2 Less Frequent Dosing Approved in US for Lucentis
4.6.3 New Indications for Lucentis
4.6.4 Possible Combination Therapy Involving Lucentis
4.7 Avastin (bevacizumab) - Roche
4.7.1 Avastin: Sales Forecast 2017-2028
4.7.2 Compounding Pharmacies and Safety Risks
4.8 Visudyne (verteporfin) - Valeant/ Novartis
4.8.1 Visudyne: Sales Forecast 2017-2028
4.9 Jetrea (ocriplasmin) - ThromboGenics/ Novartis
4.9.1 Jetrea: Recent Sales Performance
4.9.2 Clinical Study Plans for Jetrea
4.9.3 Jetrea: Sales Forecast 2017-2028
4.9.4 Possible Acquisition Move on ThromboGenics
4.9.5 R&D Agreements with Eleven Biotherapeutics and Bicycle Therapeutics
4.10 Other Retinal Disorder Drugs
4.10.1 Iluvien (fluocinolone implant) - Alimera Sciences
4.10.2 Ozurdex (dexamethasone implant) - Allergan
4.10.3 Other Retinal Disorder Drugs: Sales Forecast 2017-2028
5. Allergic, Inflammatory & Infective Drugs Market: Market Analysis and Forecast 2017-2028
5.1 Leading Products in The Allergic, Inflammatory and Infective Drugs Market, 2017
5.2 Allergic, Inflammatory and Infective Drugs: Market Trends and Developments, 2017
5.2.1 The Growth Prospects for Allergic, Inflammatory and Infective Drugs
5.2.2 Topical NSAIDs Launched: Prolensa and Ilevro
5.3 Allergic, Inflammatory and Infective Drugs: Market Forecast 2017-2028
5.3.1 Allergic, Inflammatory and Infective Drugs: Changing Market Shares by Leading Drugs 2017-2028
5.4 Leading Drugs for The Treatment of Allergic, Inflammatory and Infective Ophthalmic Conditions
5.5 Patanol And Pataday (olopatadine) - Alcon (Novartis)
5.5.1 Pataday: Sales Forecast 2017-2028
5.5.2 Impending Generic Competition for Patanol And Pataday
5.5.3 Approval of Pazeo Solution
5.5.4 Patanol: Sales Forecast 2017-2028
5.6 Vigamox (moxifloxacin) – Alcon (Novartis)
5.6.1 Intensifying Competition and Generics Drug Challenge to Vigamox
5.6.2 Moxeza: A Next-Generation Form of Vigamox
5.6.3 Vigamox: Sales Forecast 2017-2028
5.7 TobraDex (tobramycin/dexamethasone) – Alcon (Novartis)
5.7.1 The Development and Commercialisation of TobraDex ST
5.7.2 TobraDex: Sales Forecast 2017-2028
5.8 Cravit (levofloxacin) - Santen
5.8.1 Cravit: Sales Forecast 2017-2028
5.9 Acular (ketorolac) – Allergan (Actavis)
5.9.1 Acular: Sales Forecast 2017-2028
5.10 AzaSite (azithromycin) - Akorn
5.10.1 AzaSite: Sales Forecast 2017-2028
5.11 Other Allergic, Inflammatory, and Infective Drugs: Sales Forecast 2017-2028
6. Glaucoma Drugs Market: Market Analysis and Forecast 2017-2028
6.1 Glaucoma Drugs: Market Overview
6.1.1 Leading Products in The Glaucoma Drugs Market, 2017
6.2 Glaucoma Drugs: Market Trends and Developments, 2017
6.2.1 Patent Expiration: A Major Restraint for Glaucoma Drugs
6.2.2 Preservative-Free Formulation Trends
6.2.3 Innovation in Treatments for Glaucoma
6.3 Simbrinza: First Beta-Blocker-Free Combination
6.4 Glaucoma Drugs: Market Forecast 2017-2028
6.4.1 Glaucoma Drugs: Changing Market Shares by Leading Drugs 2017-2028
6.5 Leading Drugs for The Treatment of Glaucoma
6.6 Lumigan And Ganfort (bimatoprost) – Allergan (Actavis)
6.6.1 Lumigan And Ganfort: Sales Forecast 2017-2028
6.7 Xalatan And Xalacom (latanoprost) - Pfizer
6.7.1 Xalatan/Xalacom: Sales Forecast 2017-2028
6.8 Travatan/Travatan Z and DuoTrav (travoprost) - Novartis
6.8.1 Travatan/Travatan Z and DuoTrav: Sales Forecast 2017-2028
6.9 Alphagan/Alphagan P and Combigan (brimonidine) - Allergan
6.9.1 Alphagan/Alphagan P and Combigan: Sales Forecast 2017-2028
6.10 Trusopt And Cosopt/Cosopt PF (dorzolamide) – Merck/ Santen
6.10.1 Divestment Agreement with Santen And Akorn
6.10.2 Trusopt: Sales Forecast 2017-2028
6.10.3 Cosopt And Cosopt PF: Sales Forecast 2017-2028
6.11 Azopt (brinzolamide) - Novartis
6.11.1 Azopt: Sales Forecast 2017-2028
6.12 Tapros (tafluprost) – Santen
6.12.1 Tapros: Sales Forecast 2017-2028
6.13 Zioptan (tafluprost) - Akorn
6.13.1 Zioptan: Sales Forecast 2017-2028
6.14 Other Glaucoma Drugs: Sales Forecast 2017-2028
7. Dry Eye Drugs Market: Market Analysis and Forecast 2017-2028
7.1 Dry Eye Drugs: Market Overview
7.1.1 Leading Products in The Dry Eye Drugs Market, 2017
7.2 Dry Eye Drugs: Market Trends and Developments, 2016
7.2.1 Restasis: Patent Elongations and Generic Challenges Creating Uncertainty
7.2.2 Intensifying Research Focused on Dry Eye
7.2.3 Improving Diagnostic Tools
7.3 Dry Eye Drugs: Market Forecast 2017-2028
7.3.1 Dry Eye Drugs: Changing Market Shares by Leading Drugs 2017-2028
7.4 Leading Drugs for The Treatment of Dry Eye
7.5 Restasis (ciclosporin) – Allergan (Actavis)
7.5.1 Restasis – Generic launch in 2016?
7.5.2 Restasis: Sales Forecast 2017-2028
7.6 Refresh Brand Products – Allergan (Actavis)
7.6.1 Refresh Brand Products: Sales Forecast 2017-2028
7.7 Hyalein (hyaluronic acid) - Santen
7.7.1 Hyalein: Sales Forecast 2017-2028
7.8 Diquas (diaquafosol) - Santen
7.8.1 Diquas: Sales Forecast 2017-2028
7.9 Other Dry Eye Drugs: Sales Forecast 2017-2028
7.10 Other Ophthalmic Drugs
7.10.1 Hetlioz (tasimelteon) - Vanda Pharmaceuticals
7.10.2 Hetlioz: Sales Forecast 2017-2028
8. Leading National Markets for Ophthalmic Drugs, 2017-2028
8.1 The Ophthalmic Drugs Market by Region
8.1.1 The Global Distribution of Ophthalmic Drugs In 2017
8.2 Leading National Markets: Forecast 2017-2028
8.2.1 Changing Market Shares by Region, 2017-2028
8.3 Regional Ophthalmic Drugs Markets: Analysis and Forecasts, 2017-2028
8.4 United States: The Largest Ophthalmic Drugs Market
8.4.1 How Will the Rise of a Biosimilars Market Impact on US Ophthalmic Drugs?
8.4.2 US Ophthalmic Drugs Market: Market Forecast 2017-2028
8.5 EU5
8.5.1 EU5 Ophthalmic Drugs Market: Market Forecast 2017-2028
8.5.1.1 EU5 Markets: Changing Market Shares by Country, 2017-2028
8.5.2 Germany
8.5.2.1 German Ophthalmic Drugs Market: Market Forecast 2017-2028
8.5.3 France
8.5.3.1 French Ophthalmic Drugs Market: Market Forecast 2017-2028
8.5.4 UK
8.5.4.1 UK Ophthalmic Drugs Market: Market Forecast 2017-2028
8.5.4.2 Brexit – Increased Uncertainty May Affect the UK Ophthalmic Drug Market
8.5.5 Italy
8.5.5.1 Italian Ophthalmic Drugs Market: Market Forecast 2017-2028
8.5.6 Spain
8.5.6.1 Spanish Ophthalmic Drugs Market: Market Forecast 2017-2028
8.6 Japan
8.6.1 The Cost of Treatment in Japan
8.6.2 Japanese Pharmaceutical Industry Regulatory Reform
8.6.3 Japanese Ophthalmic Drugs Market Forecast 2017-2028
8.7 China
8.7.1 Expansion of Healthcare Coverage and Reimbursement in China
8.7.2 Price Controls and The Anhui Model
8.7.3 Chinese Ophthalmic Drugs Market: Market Forecast 2017-2028
8.8 Brazil
8.8.1 How Will Brazil’s Growing Healthcare Influence Ophthalmic Drugs
8.8.2 Brazilian Ophthalmic Drugs Market: Market Forecast 2017-2028
8.9 Russia
8.9.1 How Will Russia’s Economic Status Affect Its Pharma Industry?
8.9.2 Russian Ophthalmic Drugs Market: Market Forecast 2017-2028
8.10 India
8.10.1 The Impact of The Drug Prices Control Order on Indian Pharma
8.10.2 India’s Expansion of Healthcare Provision
8.10.3 Indian Ophthalmic Drugs Market: Market Forecast 2017-2028
8.11 Rest of the World
8.11.1 Rest of the World Ophthalmic Drugs Market: Market Forecast 2017-2028
9. Leading Companies in the Ophthalmic Drugs Market, 2017-2028
9.1 Ophthalmic Drugs – A Changing Market Landscape
9.2 Leading Companies in The Ophthalmic Drugs Market, 2017
9.2.1 Ophthalmic Drugs Market: Leading Companies Forecast 2017-2028
9.2.2 Ophthalmic Drugs: Changing Market Shares by Leading Companies 2017-2028
9.3 Novartis (Alcon)
9.3.1 Novartis: Ophthalmic Drugs Portfolio, 2016
9.3.2 Novartis: Sales Forecast 2017-2028
9.3.3 Novartis: Ophthalmic Drugs Development Pipeline, 2016
9.3.4 Novartis: Recent Developments
9.3.4.1 Novartis Restructures Following Strategic Review
9.3.4.2 Novartis Licenses Ophthotech’s Fovista
9.4 Regeneron
9.4.1 Regeneron: Ophthalmic Drugs Portfolio, 2016
9.4.2 Regeneron: Recent Developments
9.4.2.1 Expanding Indications for Eylea
9.4.2.2 Eylea/Zaltrap and the Davis-Smyth Patent Agreements
9.4.3 Regeneron: Sales Forecast 2017-2028
9.4.4 Regeneron: Ophthalmic Drugs Development Pipeline, 2016
9.5 Allergan (Actavis)
9.5.1 Allergan: Ophthalmic Drugs Portfolio
9.5.2 Allergan: Recent Developments
9.5.2.1 Ozurdex (Dexamethasone Intravitreal Implant): The First Drug Therapy for Diabetic Macular Oedema
9.5.2.2 How Real Is the Threat of Generic Restasis?
9.5.2.3 Valeant’s Attempted Takeover Squashed by Actavis Bid
9.5.3 New acqusitions for healthcare development
9.5.4 Allergan: Sales Forecast 2017-2028
9.5.5 Allergan: Ophthalmic Drugs Development Pipeline, 2017
9.6 Roche
9.6.1 Roche: Ophthalmic Drugs Portfolio, 2016
9.6.1.1 Lucentis: US Sales Forecast 2017-2028
9.6.2 Roche: Sales Forecast 2017-2028
9.6.3 Roche: Ophthalmic Drugs Development Pipeline, 2016
9.7 Valeant
9.7.1 Valeant: Ophthalmic Drugs Portfolio, 2015
9.7.2 Valeant: Recent Developments
9.7.2.1 Valeant’s Acquisition of Bausch and Lomb Still Driving Its Ophthalmic Portfolio
9.7.3 Valeant: Sales Forecast 2017-2028
9.7.4 Valeant: Ophthalmic Drugs Development Pipeline, 2016
9.7.5 Valeant: Difficult End to 2015 as well as 2016 Leads to Uncertainty About Company Future
9.8 Santen
9.8.1 Santen: Ophthalmic Drugs Portfolio, 2016
9.8.2 Santen: Recent Developments
9.8.2.1 Santen Acquires Novagali Pharma
9.8.2.2 Santen Acquires Merck’s Ophthalmic Drugs Portfolio
9.8.3 Santen: Sales Forecast 2017-2028
9.8.4 Santen: Ophthalmic Drugs Development Pipeline, 2016
9.9 Bayer
9.9.1 Bayer: Ophthalmic Drugs Portfolio
9.9.2 Bayer: Sales Forecast 2017-2028
9.10 Pfizer
9.10.1 Pfizer: Ophthalmic Drugs Portfolio, 2017
9.10.1.1 Xalatan/Xalacom – Pfizer’s Leading Ophthalmic Products
9.10.1.2 Macugen - Valeant/Pfizer
9.10.2 Pfizer: Recent Developments
9.10.2.1 Pfizer Attempts to Acquire AstraZeneca
9.10.2.2 Pfizer Attempts Merger with Allergan
9.10.3 Pfizer: Sales Forecast 2017-2028
9.10.4 Pfizer: Ophthalmic Drugs Development Pipeline, 2017
9.11 Senju
9.11.1 Senju: Ophthalmic Drugs Portfolio
9.11.2 Senju: Sales Forecast 2017-2028
9.11.3 Senju: Ophthalmic Drugs Development Pipeline, 2016
9.11.3.1 Y 39983 (SNJ 1656)
9.11.3.2 Difluprednate (SJE-2079)
10. Ophthalmic Drugs: Research and Development Pipeline, 2017-2028
10.1 The Ophthalmic Drugs Pipeline: Intensive Development Efforts in Retinal Disorders
10.2 Drugs for Retinal Disorders: Development Pipeline, 2016
10.2.1 Will Bevasiranib (RXi Pharmaceuticals) Resume Development?
10.3 Retinal Disorders: Filed or Recently Launched
10.3.1 CompaqSipp (conbercept) – Chengdu Kanghong Pharmaceutical
10.3.2 Lipidil (fenofibrate) - Abbott
10.3.3 Iluvien (fluocinolone) – AlimeraSciences
10.4 Drugs in Phase 3 Development For Retinal Disorders
10.4.1 AGN150998 And MP0260 (Anti-VEGFDARPins) - Allergan
10.4.2 Fovista and Zimura – Ophthotech Corporation
10.4.3 Lampalizumab (anti-FactorD Fab) - Roche
10.4.4 MC-1101 (hydralazine) – Macu CLEAR
10.4.5 Squalamine (anti-angiogenic drug) - OHRPharmaceutical
10.4.6 Tandospirone (serotonin 1A agonist) – Alcon (Novartis)
10.4.7 UF-021 (unoprostone) - R-TechUeno
10.5 Drugs in Phase 2 Development for Retinal Disorders
10.5.1 AKB-9778 (Tie2 activator) - AerpioTherapeutics
10.5.2 Luminate (ALG-1001; Integrin peptide therapy) - Allegro/Senju
10.5.3 AGN208397 (beclomethasone) - Allergan
10.5.4 CPC 551 - ColbyPharmaceutical
10.5.5 ESBA1008 (anti-VEGF mAb) – Alcon (Novartis)
10.5.6 iCo-007 (antisense inhibitor of C-raf kinase mRNA) - iCo Therapeutics
10.5.7 LFG316 (anti-C5 mAb) - Novartis
10.5.8 Intravitreal brimonidine implant - Allergan
10.5.9 Optina (danazol) - AmpioPharmaceuticals
10.5.10 PF-655 (synthetic siRNA) - Quark/Pfizer
10.5.11 Premiplex (SHP-607) - Shire
10.5.12 Renexus (ciliary neurotrophic factor) - Neurotech
10.5.13 Zybrestat (fosbretabulin) - Oxigene/SymphonyVIDA
10.6 DrugsInPhase 1 and Pre-clinical Developmentfor RetinalDisorders
10.6.1 BDM-E - BioDiem
10.6.2 NADPHOxidaseInhibitors – AlimeraSciences
10.6.3 PAN-90806 (topical VEGF inhibitor) - PanOptica
10.6.4 PlasmaKallikreinInhibitors (KVD001) - KalVista
10.6.5 QLT091001 (synthetic retinoid) – QLT
10.7 Drugs in Phase 3 Development for Allergic, Inflammatory and Infective Ophthalmic Conditions
10.7.1 EGP-437 (dexamethasone) – EyeGatePharmaceuticals
10.7.2 IBI-10090 and IBI-20089 - IconBioscience
10.7.3 KPI-121 (loteprednol etabonate) - Kala
10.8 Drugs in Phase 2 Development for Allergic, Inflammatory and Infective Ophthalmic Conditions
10.8.1 CF101 (adenosine A3 receptor agonist) - Can-FiteBioPharma and OphthaliX
10.8.2 FST-100 (povidone-iodine/dexamethasone) - Shire
10.8.3 NVC-422 (auriclosene) - NovaBay
10.8.4 Sarilumab - Regeneron
10.9 Drugs in Phase 1 And Pre-clinical Development for Allergic, Inflammatory and Infective Ophthalmic Conditions
10.9.1 Finafloxacin - MerLionPharmaceuticals/Novartis
10.10 Drugs for Glaucoma: Development Pipeline, 2016
10.11 Drugs in Phase 2&3 Development for Glaucoma
10.11.1 Latanoprostene Bunod (VESNEO; BOL 303259-X) - Valeant
10.11.2 AMA0076 (ROCK inhibitor) - Amakem
10.11.3 Rhopressa (AR-13324; ROCK and NET inhibitor) AndRoclatan (PG324; ROCK inhibitor) – Aerie Pharmaceuticals
10.12 Drugs in Phase 1 And Pre-clinical Development for Glaucoma
10.13 Drugs in Phase 3 Development for Dry Eye
10.13.1 EBI-005 (IL-1R antagonist) – Eleven Biotherapeutics
10.13.2 Lifitegrast (integrin antagonist) - Shire
10.13.3 Tavilermide (formerly MIM-D3tyrosine kinase receptor antagonist) - Allergan
10.13.4 SI-614 (modified hyaluronate) - Seikagaku
10.14 Drugs in Phase 2 Development for Dry Eye
10.14.1 ESBA105 (TNF-alpha antibody) - Alcon (Novartis)
10.14.2 Kineret (anakinra: IL-1 receptor antagonist) - Amgen/Sobi
10.15 Other Drugs in the Development Pipeline for Ophthalmic Conditions
10.15.1 Brimonidine For Eye Whitening - Valeant
10.15.2 GS-101 (aganirsen) - GeneSignal
10.15.3 Omidria (phenylephrine/ketorolac) – Omeros
11. Qualitative Analysis of the Ophthalmic Drugs Market, 2017-2028
11.1 Market Factors Influencing Ophthalmic Drugs
11.2 SWOT Analysis of the Global Ophthalmic Drugs Market, 2017-2028
11.3 Strengths
11.3.1 A Healthy R&D Pipeline
11.3.2 Advances in Drug Delivery Technologies
11.3.3 Support for Reimbursement and Payment Approvals
11.3.4 Gene Therapy and RNAi Technology
11.3.5 New Ophthalmic Therapeutic Applications for Drugs
11.3.6 Development of Neuroprotective Anti-Glaucoma Medications
11.3.7 Biomarkers as Tools for Better Diagnosis and Treatment
11.4 Weaknesses
11.4.1 Low Levels of Patient Adherence to Treatment
11.4.2 High Treatment Burden on Patients and Healthcare Providers
11.4.3 Under-Diagnosis and Under-Treatment
11.5 Opportunities
11.5.1 Sustained-Release Ocular Implants
11.5.2 The Impact of a Rapidly Ageing Global Population
11.5.3 Increasing Prevalence of Diabetes and Ocular Disease
11.5.4 Glaucoma and Retinal Disorders Set for Most-Marked Increases in Prevalence
11.5.5 Unmet Clinical Need in Many Disease Areas
11.5.6 Economic Growth in Emerging Market Provide Opportunity for Expansion
11.6 Threats
11.6.1 Intensifying Price Regulation in The Market
11.6.2 Generic Competition – Likely to Cause Erosion of Sales for Market Leading Brands
11.6.3 Rising Cost Of R&D
11.6.4 Biosimilars – A Bigger Threat than Generics?
11.7 Porter’s Five Force Analysis of The Global Ophthalmic Drugs Market, 2017-2028
11.7.1 Threat of New Entrants
11.7.2 Rivalry Among Competitors
11.7.3 Power of Suppliers
11.7.4 Threat of Substitutes
11.7.5 Power of Buyers
12. Conclusions
12.1 Overview of Current Market Conditions and Market Forecast, 2017-2028
12.2 Leading Sectors in Ophthalmic Drugs In 2017
12.3 Leading Regions in the Ophthalmic Drugs Market In 2017
12.4 Leading Companies in The Ophthalmic Drugs Market, 2017
12.5 What Does the Future Hold for Ophthalmic Drugs?
Appendices
Associated Report
Visiongain Report Sales Order Form
About Visiongain
Visiongain Report Evaluation Form
List of Tables
Table 2.2 Main Classes of the Glaucoma Drugs, 2016
Table 2.3 Drug Treatments for Age-Related Macular Degeneration, 2017
Table 2.4 Drug Treatments for Ocular Allergy, 2016
Table 2.5 Drug Treatments for Ocular Inflammatory Disease, 2017
Table 2.6 Drug Treatments for Eye Infections, 2017
Table 2.7 Clinical Trial Phases, 2016
Table 3.1 The Global Ophthalmic Drugs Market: Revenue ($m) and Market Share (%) by Segment, 2017
Table 3.2 The Global Ophthalmic Drugs Market: Market Forecast ($m, AGR%, CAGR%) by Sector, 2017-2028
Table 3.3 The Global Ophthalmic Drugs Market Forecast: CAGR (%) by Sector, 2017-2022, 2022-2028, 2017-2028
Table 3.4 The Global Ophthalmic Drugs Market: Revenue ($m) and Market Share (%) by Sector, 2017, 2022, 2028
Table 4.1 Top Drugs in The Retinal Disorder Drugs Market: Revenue ($m) and Market Shares (%), 2017
Table 4.2 Retinal Disorder Drugs Market: Market Forecast ($m, AGR%, CAGR%) by Leading Drugs, 2017-2028
Table 4.3 The Global Retinal Disorder Drugs Market: Market Share (%) by Leading Drugs, 2017, 2022, 2028
Table 4.4 Eylea: Regeneron/ Bayer/ Santen Sales Forecast ($m), AGR (%) and CAGR (%), 2017-2028
Table 4.5 Lucentis: Novartis/ Roche Sales Forecast ($m, AGR%, CAGR%), 2017-2028
Table 4.6 Avastin: Ophthalmic Sales Forecast ($m, AGR%, CAGR%), 2017-2028
Table 4.7 Visudyne: Sales Forecast ($m, AGR%, CAGR%), 2017-2028
Table 4.8 Jetrea: ThromboGenics/ Novartis Sales Forecast ($m, AGR%, CAGR%), 2017-2028
Table 4.9 Other Retinal Disorder Drugs: Sales Forecast ($m, AGR%, CAGR%), 2017-2028
Table 5.1 Leading Drugs in The Allergic, Inflammatory and Infective Drugs Market: Revenue ($m) and Market Shares (%), 2017
Table 5.2 Allergic, Inflammatory and Infective Drugs Market: Market Forecast ($m, AGR%, CAGR%) by Leading Drugs, 2017-2028
Table 5.3 The Global Allergic, Inflammatory and Infective Drugs Market: Market Share (%) by Leading Drugs, 2017, 2022, 2028
Table 5.4 Pataday: Novartis/Kyowa Hakko Kirin Sales Forecast ($m, AGR%, CAGR%), 2017-2028

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report